The global neurology clinical trials market size is calculated at USD 6.22 billion in 2025 and is forecasted to reach around USD 10.14 billion by 2034, accelerating at a CAGR of 5.58% from 2025 to 2034. The North America neurology clinical trials market size surpassed USD 2.83 billion in 2024 and is expanding at a CAGR of 5.61% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Neurology Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Neurology Clinical Trials Market, by Phase
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast
8.1.4. Phase IV Dessert
8.1.4.1. Market Revenue and Forecast
9.1. Neurology Clinical Trials Market, by Study Design
9.1.1. Interventional
9.1.1.1. Market Revenue and Forecast
9.1.2. Observational
9.1.2.1. Market Revenue and Forecast
9.1.3. Expanded Access
9.1.3.1. Market Revenue and Forecast
10.1. Neurology Clinical Trials Market, by Indication
10.1.1. Epilepsy
10.1.1.1. Market Revenue and Forecast
10.1.2. Parkinson’s Disease (PD)
10.1.2.1. Market Revenue and Forecast
10.1.3. Huntington’s Disease
10.1.3.1. Market Revenue and Forecast
10.1.4. Stroke
10.1.4.1. Market Revenue and Forecast
10.1.5. Traumatic Brain Injury (TBI)
10.1.5.1. Market Revenue and Forecast
10.1.6. Amyotrophic Lateral Sclerosis (ALS)
10.1.6.1. Market Revenue and Forecast
10.1.7. Muscle Regeneration
10.1.7.1. Market Revenue and Forecast
10.1.8. Others
10.1.8.1. Market Revenue and Forecast
11.1. Neurology Clinical Trials Market, by Study Design
11.1.1. Epilepsy
11.1.1.1. Market Revenue and Forecast
11.1.2. Parkinson’s Disease (PD)
11.1.2.1. Market Revenue and Forecast
11.1.3. Huntington’s Disease
11.1.3.1. Market Revenue and Forecast
11.1.4. Stroke
11.1.4.1. Market Revenue and Forecast
11.1.5. Traumatic Brain Injury (TBI)
11.1.5.1. Market Revenue and Forecast
11.1.6. Amyotrophic Lateral Sclerosis (ALS)
11.1.6.1. Market Revenue and Forecast
11.1.7. Muscle Regeneration
11.1.7.1. Market Revenue and Forecast
11.1.8. Others
11.1.8.1. Market Revenue and Forecast
12.1. Neurology Clinical Trials Market, by Phase
12.1.1. Epilepsy
12.1.1.1. Market Revenue and Forecast
12.1.2. Parkinson’s Disease (PD)
12.1.2.1. Market Revenue and Forecast
12.1.3. Huntington’s Disease
12.1.3.1. Market Revenue and Forecast
12.1.4. Stroke
12.1.4.1. Market Revenue and Forecast
12.1.5. Traumatic Brain Injury (TBI)
12.1.5.1. Market Revenue and Forecast
12.1.6. Amyotrophic Lateral Sclerosis (ALS)
12.1.6.1. Market Revenue and Forecast
12.1.7. Muscle Regeneration
12.1.7.1. Market Revenue and Forecast
12.1.8. Others
12.1.8.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Phase
13.1.2. Market Revenue and Forecast, by Study Design
13.1.3. Market Revenue and Forecast, by Indication
13.1.4. Market Revenue and Forecast, by Study Design
13.1.5. Market Revenue and Forecast, by Phase
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Phase
13.1.6.2. Market Revenue and Forecast, by Study Design
13.1.6.3. Market Revenue and Forecast, by Indication
13.1.6.4. Market Revenue and Forecast, by Study Design
13.1.6.5. Market Revenue and Forecast, by Phase
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Phase
13.1.7.2. Market Revenue and Forecast, by Study Design
13.1.7.3. Market Revenue and Forecast, by Indication
13.1.7.4. Market Revenue and Forecast, by Study Design
13.1.7.5. Market Revenue and Forecast, by Phase
13.2. Europe
13.2.1. Market Revenue and Forecast, by Phase
13.2.2. Market Revenue and Forecast, by Study Design
13.2.3. Market Revenue and Forecast, by Indication
13.2.4. Market Revenue and Forecast, by Study Design
13.2.5. Market Revenue and Forecast, by Phase
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Phase
13.2.6.2. Market Revenue and Forecast, by Study Design
13.2.6.3. Market Revenue and Forecast, by Indication
13.2.7. Market Revenue and Forecast, by Study Design
13.2.8. Market Revenue and Forecast, by Phase
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Phase
13.2.9.2. Market Revenue and Forecast, by Study Design
13.2.9.3. Market Revenue and Forecast, by Indication
13.2.10. Market Revenue and Forecast, by Study Design
13.2.11. Market Revenue and Forecast, by Phase
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Phase
13.2.12.2. Market Revenue and Forecast, by Study Design
13.2.12.3. Market Revenue and Forecast, by Indication
13.2.12.4. Market Revenue and Forecast, by Study Design
13.2.13. Market Revenue and Forecast, by Phase
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Phase
13.2.14.2. Market Revenue and Forecast, by Study Design
13.2.14.3. Market Revenue and Forecast, by Indication
13.2.14.4. Market Revenue and Forecast, by Study Design
13.2.15. Market Revenue and Forecast, by Phase
13.3. APAC
13.3.1. Market Revenue and Forecast, by Phase
13.3.2. Market Revenue and Forecast, by Study Design
13.3.3. Market Revenue and Forecast, by Indication
13.3.4. Market Revenue and Forecast, by Study Design
13.3.5. Market Revenue and Forecast, by Phase
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Phase
13.3.6.2. Market Revenue and Forecast, by Study Design
13.3.6.3. Market Revenue and Forecast, by Indication
13.3.6.4. Market Revenue and Forecast, by Study Design
13.3.7. Market Revenue and Forecast, by Phase
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Phase
13.3.8.2. Market Revenue and Forecast, by Study Design
13.3.8.3. Market Revenue and Forecast, by Indication
13.3.8.4. Market Revenue and Forecast, by Study Design
13.3.9. Market Revenue and Forecast, by Phase
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Phase
13.3.10.2. Market Revenue and Forecast, by Study Design
13.3.10.3. Market Revenue and Forecast, by Indication
13.3.10.4. Market Revenue and Forecast, by Study Design
13.3.10.5. Market Revenue and Forecast, by Phase
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Phase
13.3.11.2. Market Revenue and Forecast, by Study Design
13.3.11.3. Market Revenue and Forecast, by Indication
13.3.11.4. Market Revenue and Forecast, by Study Design
13.3.11.5. Market Revenue and Forecast, by Phase
13.4. MEA
13.4.1. Market Revenue and Forecast, by Phase
13.4.2. Market Revenue and Forecast, by Study Design
13.4.3. Market Revenue and Forecast, by Indication
13.4.4. Market Revenue and Forecast, by Study Design
13.4.5. Market Revenue and Forecast, by Phase
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Phase
13.4.6.2. Market Revenue and Forecast, by Study Design
13.4.6.3. Market Revenue and Forecast, by Indication
13.4.6.4. Market Revenue and Forecast, by Study Design
13.4.7. Market Revenue and Forecast, by Phase
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Phase
13.4.8.2. Market Revenue and Forecast, by Study Design
13.4.8.3. Market Revenue and Forecast, by Indication
13.4.8.4. Market Revenue and Forecast, by Study Design
13.4.9. Market Revenue and Forecast, by Phase
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Phase
13.4.10.2. Market Revenue and Forecast, by Study Design
13.4.10.3. Market Revenue and Forecast, by Indication
13.4.10.4. Market Revenue and Forecast, by Study Design
13.4.10.5. Market Revenue and Forecast, by Phase
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Phase
13.4.11.2. Market Revenue and Forecast, by Study Design
13.4.11.3. Market Revenue and Forecast, by Indication
13.4.11.4. Market Revenue and Forecast, by Study Design
13.4.11.5. Market Revenue and Forecast, by Phase
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Phase
13.5.2. Market Revenue and Forecast, by Study Design
13.5.3. Market Revenue and Forecast, by Indication
13.5.4. Market Revenue and Forecast, by Study Design
13.5.5. Market Revenue and Forecast, by Phase
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Phase
13.5.6.2. Market Revenue and Forecast, by Study Design
13.5.6.3. Market Revenue and Forecast, by Indication
13.5.6.4. Market Revenue and Forecast, by Study Design
13.5.7. Market Revenue and Forecast, by Phase
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Phase
13.5.8.2. Market Revenue and Forecast, by Study Design
13.5.8.3. Market Revenue and Forecast, by Indication
13.5.8.4. Market Revenue and Forecast, by Study Design
13.5.8.5. Market Revenue and Forecast, by Phase
14.1. IQVIA
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Biogen
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Aurora Healthcare
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. GlaxoSmithKline Plc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Icon Plc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Syneous Health
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Charles River Laboratories
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Med pace
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Covance
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Novartis AG
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample